

- [27] **Cavezzi A, Troiani E, Corrao S.** COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. *Clin Pract.* 2020; **10**:1271.
- [28] **Edeas M, Saleh J, Peyssonnaux C.** Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? *Int J Infect Dis.* 2020; **97**:303-5.
- [29] **Bolondi G, Russo E, Gamberini E, Circelli A, Meca MCC, Brogi E,** et al. Iron metabolism and lymphocyte characterisation during Covid-19 infection in ICU patients: an observational cohort study. *World J Emerg Surg.* 2020; **15**:41.
- [30] **Perricone C, Bartoloni E, Bursi R, Cafaro G, Guidelli GM, Shoenfeld Y,** et al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. *Immunol Res.* 2020; **68**:213-24.
- [31] **Chang R, Ng TB, Sun WZ.** Lactoferrin as potential preventative and adjunct treatment for COVID-19. *Int J Antimicrob Agents.* 2020; **56**:106118.
- [32] **Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J,** et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering (Beijing).* 2020; **6**:1192-8.
- [33] **Ghasemnejad-Berenji M, Pashapour S.** Favipiravir and COVID-19: A Simplified Summary. *Drug Res (Stuttg).* 2021; **71**:166-70.